MEMPHIS, Tenn.--(BUSINESS WIRE)--Memphis-based Computable Genomix today announced that it has secured an investment to pilot a novel process for developing genetic biomarker tests. Biomarkers are used to predict how a person will respond to drug therapy or to determine their risk of contracting a disease.
